Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minnesota.
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, University of Florida College of Medicine, Gainesville.
JAMA Surg. 2023 Sep 1;158(9):965-973. doi: 10.1001/jamasurg.2023.2934.
Endovascular aneurysm repair (EVAR) is the dominant treatment strategy for abdominal aortic aneurysms, encompassing 80% of all repairs in the United States. Endoleaks are ubiquitous and affect 30% of patients treated by EVAR, potentially leading to sac enlargement and increased risk of rupture. The care of EVAR patients requires long-term surveillance by a multidisciplinary team. Accordingly, physicians should be familiar with the fundamentals of endoleak management to achieve optimal outcomes, including timely referral for remediation or providing counseling and reassurance when needed.
PubMed and the Cochrane database were searched for articles published between January 2002 and December 2022 in English, addressing epidemiology, diagnosis, and management of endoleaks after EVAR. Endoleaks can be detected intraoperatively or years later, making lifelong surveillance mandatory. Type I and III have the highest risk of rupture (7.5% at 2 years and 8.9% at 1 year, respectively) and should be treated when identified. Intervention should be considered for other types of endoleak when associated with aneurysm sac growth larger than 5 mm based on current guidelines. Type II endoleaks are the most common, accounting for 50% of all endoleaks. Up to 90% of type II endoleaks resolve spontaneously or are not associated with sac enlargement, requiring only observation. Although the risk of rupture is less than 1%, cases that require reintervention are challenging. Recurrence is common despite endovascular treatment, and rupture can occur without evidence of sac growth. Type IV endoleaks and endotension are uncommon, are typically benign, and primarily should be observed.
Endoleak management depends on the type and presence of sac expansion. Type I and III endoleaks require intervention. Type II endoleaks should be observed and treated selectively in patients with significant sac expansion. Since endoleaks can appear any time after EVAR, at least 1 contrast-enhanced computed tomographic angiogram or duplex ultrasound by an experienced laboratory is recommended every 5 years.
血管内动脉瘤修复术(EVAR)是治疗腹主动脉瘤的主要治疗策略,涵盖了美国所有修复术的 80%。内漏是普遍存在的,影响了 30%接受 EVAR 治疗的患者,可能导致囊腔增大和破裂风险增加。EVAR 患者的治疗需要多学科团队的长期监测。因此,医生应该熟悉内漏管理的基础知识,以达到最佳治疗效果,包括及时转介修复或在需要时提供咨询和安慰。
在 2002 年 1 月至 2022 年 12 月期间,以英文发表的关于 EVAR 后内漏的流行病学、诊断和管理的文章在 PubMed 和 Cochrane 数据库中进行了检索。内漏可以在手术中或数年后被发现,因此需要终身监测。I 型和 III 型内漏破裂风险最高(分别为 2 年内 7.5%和 1 年内 8.9%),一经发现应予以治疗。根据目前的指南,当其他类型的内漏与动脉瘤囊腔增大大于 5mm 相关时,应考虑干预。II 型内漏最为常见,占所有内漏的 50%。高达 90%的 II 型内漏会自发消退或不伴囊腔增大,仅需观察。虽然破裂风险小于 1%,但需要再次介入的病例具有挑战性。尽管经过血管内治疗,复发很常见,而且破裂可能在没有囊腔增大的情况下发生。IV 型内漏和内张力不常见,通常为良性,主要应观察。
内漏管理取决于类型和囊腔扩张的存在。I 型和 III 型内漏需要干预。II 型内漏应观察并选择性治疗在有明显囊腔扩张的患者。由于内漏可能在 EVAR 后任何时间出现,建议至少每 5 年进行 1 次由经验丰富的实验室进行的增强 CT 血管造影或双功超声检查。